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ABSTRACT
Background T- cell- engaging CD3- bispecific antibodies 
(CD3- bsAbs) are promising modalities for cancer 
immunotherapy. Although this therapy has reached clinical 
practice for hematological malignancies, the absence of 
sufficient infiltrating T cells is a major barrier for efficacy in 
solid tumors. In this study, we exploited oncolytic reovirus 
as a strategy to enhance the efficacy of CD3- bsAbs in 
immune- silent solid tumors.
Methods The mutant p53 and K- ras induced murine 
pancreatic cancer model KPC3 resembles human 
pancreatic ductal adenocarcinomas with a desmoplastic 
tumor microenvironment, low T- cell density and resistance 
to immunotherapy. Immune- competent KPC3 tumor- 
bearing mice were intratumorally injected with reovirus 
type 3 Dearing strain and the reovirus- induced changes 
in the tumor microenvironment and spleen were analyzed 
over time by NanoString analysis, quantitative RT- PCR 
and multicolor flow cytometry. The efficacy of reovirus in 
combination with systemically injected CD3- bsAbs was 
evaluated in immune- competent mice with established 
KPC3 or B16.F10 tumors, and in the close- to- patient 
human epidermal growth factor receptor 2 (HER2)+ breast 
cancer model BT474 engrafted in immunocompromised 
mice with human T cells as effector cells.
Results Replication- competent reovirus induced an early 
interferon signature, followed by a strong influx of natural 
killer cells and CD8+ T cells, at the cost of FoxP3+ Tregs. 
Viral replication declined after 7 days and was associated 
with a systemic activation of lymphocytes and the 
emergence of intratumoral reovirus- specific CD8+ T cells. 
Although tumor- infiltrating T cells were mostly reovirus- 
specific and not tumor- specific, they served as non- 
exhausted effector cells for the subsequently systemically 
administered CD3- bsAbs. Combination treatment of 
reovirus and CD3- bsAbs led to the regression of large, 
established KPC3, B16.F10 and BT474 tumors. Reovirus as 
a preconditioning regimen performed significantly better 
than simultaneous or early administration of CD3- bsAbs. 
This combination treatment induced regressions of distant 
lesions that were not injected with reovirus, and systemic 
administration of both reovirus and CD3- bsAbs also led to 
tumor control. This suggests that this therapy might also 
be effective for metastatic disease.
Conclusions Oncolytic reovirus administration represents 
an effective strategy to induce a local interferon response 
and strong T- cell influx, thereby sensitizing the tumor 
microenvironment for subsequent CD3- bsAb therapy. 
This combination therapy warrants further investigation in 
patients with non- inflamed solid tumors.
BACKGROUND
T- cell- engaging bispecific antibodies (bsAbs) 
are emerging as a potent therapeutic cancer 
modality.1 These Ig- based biologicals can 
induce dramatic responses in advanced 
malignancies, as was demonstrated with the 
use of a CD3xCD19 bsAb for the treatment 
of non- Hodgkin’s lymphoma.2 Currently, 
more than 40 other T- cell- redirecting bsAbs 
are in clinical development for both hema-
tological malignancies and solid tumors.3 
CD3- bispecific antibodies (CD3- bsAbs) are 
comprised of one arm engaging a tumor- 
associated antigen (TAA) expressed on the 
cell surface of cancer cells, and a second arm 
targeting T cells via CD3.4 By tethering T 
cells to tumor cells, these CD3- bsAbs create 
a functional immunological synapse.5 This 
results in selective T- cell- mediated killing 
of the target- expressing tumor cells, for 
which both CD4+ and CD8+ T cells can be 
employed.6 Since binding and activation of 
T cells occurs via CD3, these CD3- bsAbs can 
activate T cells in an major histocompatibility 
complex (MHC) class I- and T- cell receptor- 
independent manner. CD3- bsAbs can redi-
rect a large proportion of the polyclonal 
T- cell pool toward the tumor, and thereby 
bypass the need for endogenous tumor- 
specific T cells.7 Despite the many advantages 
of these CD3- bsAbs, clinical development has 
been hampered by several factors, including 
low response rates in solid, immune- silent 
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tumors.7 Factors associated with poor response to immu-
notherapy include the absence of an interferon (IFN) 
gene signature and lack of T cells in the tumor beds, 
generally referred to as a “cold” microenvironment.8 9
Oncolytic viruses (OVs) are increasingly recognized as 
potent anticancer moieties due to their virtue to selec-
tively replicate in transformed cells and ignite an antiviral 
immune response in the malignant lesion.10 It has been 
demonstrated that OVs can sensitize resistant tumors 
for checkpoint blockade therapy.11–13 The mammalian 
reovirus type 3 Dearing strain (T3D), which is not asso-
ciated with symptomatic disease in humans, is one of the 
leading OVs under clinical evaluation and displays an 
excellent safety record in clinical trials.14 15 Reoviruses 
show an inherent preference for replication in trans-
formed, but not in healthy cells.16 17 Although reovirus 
has demonstrated some tumor regressions as a mono-
therapy in certain cancer types, such as in prostate xeno-
graft models and prostate cancer patients, its potency 
might be better manifested in rationally designed combi-
nation strategies.18 19 In this study, we employed oncolytic 
reovirus as a strategy to enhance the antitumor efficacy 
of CD3- bsAbs in solid tumors. Using fully immunocom-
petent mouse tumor models, we demonstrated that 
injection with replication- competent reovirus converted 
immunologically cold pancreatic adenocarcinoma 
tumors to inflamed sites with a strong IFN signature 
and abundance of virus- specific CD8+ T cells. This effect 
depended on viral replication, which was controlled by 
the immune system within 2 weeks. Subsequent systemic 
administration of CD3- bsAbs resulted in regressions of 
local and distant large tumors. These findings provide 
evidence that preconditioning of the tumor microenvi-
ronment (TME) with an oncolytic reovirus is an attractive 
strategy to prime immune- silent tumors for effective CD3- 
bsAb therapy (Graphical abstract).
METHODS
Virus
The wild- type reovirus strain R124 (here referred to as 
reovirus) was previously isolated from a heterogeneous 
reovirus T3D stock (VR-824) obtained from the American 
Type Culture Collection (ATCC) by two rounds of plaque 
purification using HER911 cells.20 All experiments were 
performed using cesium chloride- purified stocks (see 
online supplemental materials). The total amount of 
particles was calculated based on optical density (OD)260 
values, where 1 OD equals 2.10*1012 reovirus particles/
mL.21 The infectious titer was quantified by plaque assay 
on HER911 cells.22 Reovirus particles were inactivated 
by exposure to shortwave ultraviolet light (254 nm) for 
15 min at room temperature on a low- attachment 6- well 
plate (Corning).23 Afterward, the total amount of viral 
particles was determined based on the OD260 values. 
A correction value was calculated to ensure an equal 
number of viral particles for treatments with infectious 
and UV- inactivated reovirus (UVi).
Bispecific antibodies
The CD3xTRP1 bsAb used is a knob- into- hole bispe-
cific based on murine IgG2a with an Fc Silent mutation, 
featuring one arm with an anti- mouse CD3e single- chain 
variable fragment (scFv) based on the clone 145-2 C11, 
and the other arm containing the TA99 clone directed 
against tyrosinase- related protein-1 (TRP1) (bAb0136; 
Absolute Antibody). The CD3xHER2 bsAb comprises an 
antihuman CD3 scFv based on the clone OKT3, together 
with an anti- HER2 arm based on clone 4D5-8 (trastu-
zumab) (bAb0183; Absolute Antibody).
Cell lines
The murine pancreatic cancer cell line KPC3 is a low- 
passage derivate of a primary KPC tumor with mutant 
p53 and K- ras24 from a female C57BL/6 mouse. KPC3.
TRP1 cells were generated as described25 and selected 
for expression of TRP1 by cell sorting using an αTRP1 
antibody (clone: TA99). The murine melanoma cell line 
B16.F10 (ATCC- CRL6475) and the human breast cancer 
cell line BT474 (ATCC- HTB-20) were purchased from 
the ATCC. More information can be found in the online 
supplemental methods.
Animal experiments
Male or female C57BL/6J mice (Charles River Labora-
tories, France) of 8 weeks old were used for the KPC3 
and B16.F10 model, respectively. KPC3 or KPC3.TRP1 
tumors were inoculated by subcutaneous injection of 
1×105 (for antitumor efficacy experiments) or 2×105 (for 
intratumoral analysis experiments) cells in the right flank 
in 100–200 µL phosphate- buffered saline (PBS)/0.1% 
bovine serum albumin (BSA). For bilateral experiments, 
a second tumor was subcutaneously engrafted 1 week 
after the primary tumor on the alternate flank. B16.
F10 tumors were engrafted by subcutaneous injection of 
5×104 cells in a volume of 100 µL PBS/0.1% BSA. Female 
nonobese diabetic (NOD).Cg- PrkdcscidIl2rgtm1Wjl/SzJ 
(NSG) mice of 6 weeks old (Charles River Laboratories) 
were used for the BT474 model. BT474 tumors were 
orthotopically engrafted by injecting 5×106 cells in a 
volume of 100 µL 50:50 PBS/0.1% BSA:Growth Factor 
Reduced matrigel (Corning) in the fourth mammary fat 
pad of isoflurane- anesthesized mice. Human peripheral 
blood mononuclear cells (PBMCs) from a buffy coat of 
an anonymous consented donor (Sanquin Bloodbank, 
Amsterdam, The Netherlands) HLA- A29:02- matched to 
BT47426 were isolated by Ficoll- Paque density- gradient 
centrifugation. 5×106 PBMCs were intravenously admin-
istered to each mouse in a volume of 100 µL PBS/0.1% 
BSA. Mice with palpable tumors were allocated into 
groups with similar average tumor size and assigned a 
treatment regimen. Intratumoral reovirus administra-
tion was performed by injection of 107 plaque- forming 
units (pfu) of reovirus or PBS as control in a volume 
of 30 µL on 3 consecutive days, unless otherwise indi-
cated, while mice were under isoflurane anesthesia. 
Intravenous reovirus administration was performed by 
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injection of 107 or 108 pfu of reovirus in a volume of 100 
µL in the tail vein on 3 consecutive days. Treatment with 
CD3xTRP1 or CD3xHER2 bsAb consisted of three intra-
peritoneal injections of 12.5 µg antibody in 100 µL PBS 
given every other day. Treatment with FTY720 (Cayman 
Chemical) occurred by supplementing the mice with 2.5 
µg/mL FTY720 in their drinking water and a daily oral 
dose of 2 µg FTY720/g body weight administered orally 
via pipetting into the mouth. During all experiments, 
tumors were measured 3–6 times a week in three dimen-
sions using a caliper, in a blinded manner concerning 
the experimental group. For antitumor efficacy experi-
ments, mice were euthanized when tumors reached the 
experimental endpoint, which equals a volume of 1000 
mm3 (one- tumor model) or a combined volume of 1500 
mm3 (bilateral tumor model). Mice were censored from 
analysis when they had to be euthanized due to humane 
endpoints before reaching the experimental endpoint. 
For intratumoral analysis experiments, mice were sacri-
ficed at indicated days after treatment before tumors 
and/or spleens were collected. Tumors were divided into 
representative parts, which were either snap- frozen in 
liquid N2 and stored at −80°C until further analysis, fixed 
in 4% formaldehyde (AddedPharma) for immunohisto-
chemistry (IHC) or immediately processed to single- cell 
suspensions to analyze the cellular composition by flow 
cytometry. These procedures are described in detail in 
the online supplemental methods.
Quantification of reovirus genomic copies by quantitative 
reverse transcription PCR (RT-qPCR)
Reovirus genomic copies were quantified by RT- qPCR of 
reovirus genomic segment 4 (S4) on RNA of cells, tumors 
and other organs, as described in the online supplemental 
methods. Reovirus S4 copy numbers were determined 
based on a standard curve, generated with serial dilutions of 
plasmid pcDNA_S4. Log10 S4 copy numbers were calculated 
using a previously described formula.27
NanoString analysis
Total RNA was isolated from a representative piece 
(10–30 mg) of each tumor as described in the online 
supplemental methods. RNA quality and integrity (RQI) 
were determined using the Experion Automated Elec-
trophoresis System (Bio- Rad). Only samples with RQI 
score >8 were included for NanoString analysis. Multi-
plex gene expression was measured using the PanCancer 
Mouse Immune Profiling panel (NanoString Technolo-
gies). Two hundred nanogram of total RNA was hybrid-
ized for 17 hours, and quantified by scanning 490 Field 
Of Views using the Digital Analyzer (nCounter Flex). 
Data were processed and normalized using nSolver Anal-
ysis Software (V.4.0) and the Advanced Analysis module 
(NanoString). NanoString- defined markers were used to 
analyze cell type scores. Expression of reovirus- induced 
host genes was confirmed by RT- qPCR as described in the 
online supplemental methods.
Statistics
All graphs were prepared and statistical analyses were 
performed using the GraphPad Prism software (V.8). All 
data represent means±SEM and key data are representative 
for 2–5 experiments with similar results. Survival between 
groups was compared using Kaplan- Meier curves and the 
statistical log- rank test (Mantel- Cox). For RT- qPCR anal-
ysis, samples were excluded when RNA concentration and 
purity were too low. When comparing S4 RT- qPCR data 
between two groups, average log10 values were compared 
using a two- tailed unpaired t test. For comparing more 
groups versus PBS treatment, average log10 values were 
compared using an ordinary one- way analysis of vari-
ance (ANOVA) including Dunnett’s post hoc test. For 
flow cytometry data, tumor samples were excluded when 
evidence for draining lymph node contamination was 
present. The means of flow cytometric data of two exper-
imental groups were compared using two- tailed unpaired 
t tests. For comparing multiple groups versus PBS treat-
ment or negative control, a one- way ANOVA including 
Dunnett’s post hoc test was performed. For comparing 
multiple groups with each other, a one- way ANOVA 
including Tukey’s post hoc test was used. The association 
between two ranked variables was done by Spearman rank 
correlation. Significance levels are labeled with asterisks, 
with *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
Non- significant differences are indicated by ns.
RESULTS
Reovirus efficiently replicates but does not affect tumor 
growth in the KPC3 pancreatic cancer model
Human pancreatic tumors are often not susceptible to 
immunotherapeutic strategies, including checkpoint 
inhibition.28 29 The murine pancreatic cancer model 
KPC3 is an early derivate from the genetic pancreatic 
ductal adenocarcinoma (PDAC) KPC mouse model, 
which recapitulates many of the histopathological and 
immunological key features observed in human PDAC,30 
including acinar tubular structures, a dense desmoplastic 
stroma and absence of CD3+ T cells (online supple-
mental figure S1A,B). We previously demonstrated that 
outgrowth of KPC3 tumors with heterologous expres-
sion of the Trp1 gene (KPC3.TRP1) could significantly 
be delayed by early CD3xTRP1 bsAb therapy.25 However, 
CD3xTRP1 bsAb treatment failed to exhibit any effect on 
larger KPC3.TRP1 tumors (online supplemental figure 
S1C,D), although tumor cells were efficiently killed in 
vitro in an antigen- dependent fashion (online supple-
mental figure S1E). We hypothesized that the low T- cell 
density observed in established KPC3 tumors represents 
a major barrier to the efficacy of CD3- bsAb therapy and 
therefore explored the use of oncolytic reovirus to over-
come this barrier.
We first tested the ability of reovirus to infect and 
replicate in KPC3 cells in vitro and observed a high 
number of genomic viral copies (figure 1A) and reoviral 
protein sigma 3+ cells (figure 1B) after infection with 
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Figure 1 Reovirus efficiently replicates but does not affect tumor growth in the KPC3 pancreatic cancer model. (A) Numbers 
of reovirus genomic segment 4 (S4) copies in KPC3 cells after reovirus infection. KPC3 cells (125,000/well) were infected with 
increasing multiplicities of infection (MOIs) of reovirus, or phosphate- buffered saline (PBS) (Mock) or UV- inactivated reovirus 
(UVi) (equal number of viral particles as MOI 100) as controls. Samples (n=3) were harvested 24 hours after infection and 
reovirus S4 copy numbers were determined by quantitative reverse transcription PCR (RT- qPCR). (B) Frequency of sigma 
3- positive KPC3 cells and geometric mean fluorescence intensity (gMFI) of sigma 3 expression 48 hours after infection with 
increasing MOIs of reovirus, or PBS (Mock) or UVi as controls, analyzed by flow cytometry. Bar graphs represent mean±SEM 
of triplicates. (C) Analysis of oncolytic activity of reovirus. KPC3 cells (5000/well) were plated and infected with reovirus or 
controls. Metabolic activity was determined 48 hours after infection. Data represent mean±SEM of triplicates. (D) Design of 
experiment described in (E–G). Mice (n=4–6/group) with established KPC3 tumors were treated with intratumoral (i.t.) injections 
of 107 or 108 plaque- forming units (pfu) of reovirus on 3 consecutive days. PBS was used as control. (E) Three days after the 
last reovirus injection, tumors were harvested and reovirus S4 copy numbers were determined in tumor lysates by RT- qPCR. (F) 
Representative images obtained from immunohistochemical staining of tumors for sigma 3. Shown are tumors treated with PBS 
or reovirus 107 pfu. Scale bars equal 500 µm and 100 µm for overview and magnification, respectively. (G) Mean tumor volumes 
after treatment with PBS or reovirus 107 or 108 pfu. Dashed vertical lines indicate days of injections. Data are presented as 
mean±SEM (n=4–6/group). Significance versus PBS treatment in (E) and (G) is determined using an ordinary one- way analysis 
of variance (ANOVA) with Dunnett’s post hoc test. Significance levels: ns (not significant) and **p<0.01.
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very low multiplicities of infection (MOIs). Total 
viral copy numbers and viral load per cell increased 
with higher MOIs, and additionally, reovirus demon-
strated a dose- dependent oncolytic activity in vitro 
(figure 1C). Oncolytic activity appeared moderate as 
half of the cell culture was killed after 2 days, whereas 
all cells contained high levels of replicating virus. As 
expected, reovirus did not replicate after UV inacti-
vation in KPC3 cell cultures (figure 1A).23 To test 
the replication capacity of reovirus in vivo, KPC3 
tumor- bearing mice were intratumorally injected on 
3 consecutive days with either 107 or 108 pfu/mouse 
starting at day 13 when the tumors were established 
(figure 1D). Both viral doses resulted in high levels of 
genomic reovirus copies after 3 days, indicating effi-
cient replication in vivo (figure 1E). Hotspots of viral 
replication were seen in tumor tissue slides stained for 
sigma 3, suggesting that viral replication is not evenly 
distributed in the tumor (figure 1F). Despite this very 
efficient replication, reovirus administration failed 
to make a large impact on tumor growth (figure 1G). 
Since optimal replication was observed with 107 pfu/
mouse, we selected this dose for further experiments.
Replication-competent reovirus induces a potent IFN response 
in the tumor
Next, we studied the kinetics of reovirus replication 
in KPC3 tumor- bearing mice (figure 2A). Intratumoral 
administration of reovirus yielded high viral copy 
numbers that peaked around 1 to 3 days post injections 
(p.i.) and gradually decreased back to baseline levels 
around day 11 p.i. (figure 2B). UV- inactivated reovirus 
(UVi) did not show any amplification. Thus, reovirus 
has a limited time window of replication in the TME 
which lasted up to 10 days, suggesting that replication is 
restricted by antiviral immunity of the host. Transcrip-
tome analysis of whole KPC3 tumors using NanoString 
technology was performed to investigate the antiviral 
immune response (figure 2C and online supplemental 
figure S2A). A heatmap of all genes, differentially 
expressed on at least one of the time points, revealed 
that the number of upregulated genes peaked 7 days 
after reovirus administration (figure 2C). More than 
100 immune- related genes were upregulated (False 
Discovery Rate p<0.1 and fold change >2 compared 
with PBS) and this number severely declined after 11 
days, in parallel with viral replication (figure 2C and 
online supplemental figure S2A). Although UVi might 
still have the capacity to engage pattern recognition 
receptors (PRRs), as was previously demonstrated,31 
this inactivated reovirus did not induce upregulation 
of immune genes (figure 2C and online supplemental 
figure S2A). This suggested that the ability to repli-
cate was essential for the immunostimulatory effects of 
reovirus in the TME.
Analyses of gene expression signatures roughly 
revealed two patterns: an early expressed profile, 
including pathways such as “interferon” and “pathogen 
response,” peaking at day 1 to 5 and a late expressed 
profile, with pathways such as “T- cell functions” and 
“antigen processing,” which peaked at day 7 (figure 2D–G 
and online supplemental figure S2B). Expression of 
early IFN response genes was validated for some prime 
examples such as Ifit-1, Oas1b and Ddx58 using RT- qPCR 
(figure 2E). These antiviral genes were strongly upregu-
lated after treatment with replication- competent reovirus, 
but not UVi, and expression levels correlated strongly 
(R2 >0.6) and significantly (p<0.0001) with the number 
of viral copy numbers in the tumor (figure 2E). We also 
validated the expression of some genes involved in the 
late pathways (figure 2F), such as T- cell- attracting chemo-
kines Cxcl10, Ccl5 and MHC class I component β2m, and 
observed increased expression levels after reovirus, but 
not UVi treatment (figure 2G). The expression levels of 
these genes also significantly correlated with the number 
of viral copies present in the tumor, although to a lesser 
extent (R2<0.5) than the early induced genes. Lastly, we 
analyzed the kinetics of NanoString- defined cell type 
scores in our dataset (figure 2H). A marginal increase 
in CD45 score was observed on day 7, and when lineage- 
specific scores were examined, the score for T cells (iden-
tified by expression of Cd3g, Cd3e, Cd3d and Sh2d1a) was 
most significantly upregulated at day 7 after reovirus treat-
ment. Interestingly, natural killer (NK) cells, dendritic 
cells (DCs) and neutrophil scores were also enhanced 
on day 7. Macrophage score remained largely unaffected 
by reovirus treatment. Overall, we observed that reovirus 
replication induced a potent IFN response, including 
highly increased expression of inflammatory genes and 
T- cell- attracting chemokines.
Replication-competent reovirus recruits virus-specific T cells 
to the tumor
To validate that the reovirus- induced inflammatory 
response increased tumor infiltration by immune cells, 
we analyzed the cellular composition of the TME by flow 
cytometry and IHC (figure 3 and online supplemental 
figure S3). Interestingly, the total number of CD45+ 
immune cells in the reovirus- treated tumors was hardly 
altered (figure 3A). However, the percentage of CD3+ 
T cells within the CD45+ population was significantly 
increased after reovirus administration, starting 5 days 
after the last reovirus injection (figure 3B). This effect 
was replication- dependent since UVi treatment failed to 
increase the intratumoral T- cell density (figure 3B and 
online supplemental figure S4A). Within the CD3+ T- cell 
population, the CD8+ T cells were significantly more 
enriched compared with the CD4+ T cells, as seen by a 
significantly increased CD8+/CD4+ ratio (figure 3C,D). 
In the tumors of reovirus- injected mice, the presence of 
CD8+ T cells could be observed in both the border and 
the interior of tumors (figure 3E).
To gain a broader view on the TME, we performed a 
high- dimensional flow cytometric analysis of the lymphoid 
and myeloid cell compartments in the tumors at 5 days 
after reovirus administration (figure 3F and online 
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supplemental figure S4B–G). This analysis confirmed 
the increased contribution of CD8+ T cells (a 2.6- fold 
increase compared with PBS), as the total CD45+ immune 
infiltrate increased only 1.4- fold (online supplemental 
figure S4B). The frequency of NK cells and CD4 cells also 
significantly increased, and within the CD4+ T- cell popu-
lation, the frequency of FoxP3+ CD4+ regulatory T cells 
dramatically dropped from 40% to 10% (online supple-
mental figure S4C,D). This resulted in an enhanced ratio 
of CD8+ cytotoxic T cells to FoxP3+ regulatory T cells in 
the TME (online supplemental figure S4E). Addition-
ally, reovirus induced activation of T cells, as indicated 
by increased expression of activation marker CD44 and 
loss of adhesion marker CD62L (online supplemental 
Figure 2 Replication- competent reovirus induces a potent interferon response in the tumor. (A) Design of experiment 
described in figures (B–H). Mice (n=5/group) with established KPC3 tumors were intratumorally (i.t.) injected with 107 plaque- 
forming units (pfu) of reovirus on 3 consecutive days. Phosphate- buffered saline (PBS) or UV- inactivated reovirus (UVi) were 
used as controls and were harvested 3 days post injections (p.i.). (B) Tumors were harvested at designated days p.i., and 
reovirus genomic segment 4 (S4) copy numbers were determined in tumor lysates by quantitative reverse transcription PCR 
(RT- qPCR). (C) Heatmap of all genes that were differentially expressed in the tumor (n=3–4/group) on any day after reovirus 
treatment (False Discovery Rate p<0.1 and fold change >2 compared with PBS), as analyzed by NanoString. (D) Changes in 
signature scores on indicated days after reovirus treatment. All scores are normalized for average score of PBS. (E) Relative 
expression of interferon response genes (upper panel) as determined by RT- qPCR, and the correlation between expression and 
reovirus S4 copy numbers (lower panel). (F) Changes in signature scores on indicated days after reovirus treatment. All scores 
are normalized for average score of PBS. (G) Relative expression of genes involved in T- cell attraction and antigen processing 
(upper panel) as determined by RT- qPCR, and the correlation between expression and reovirus S4 copy numbers (lower panel). 
(H) Kinetics of specific cell type scores after reovirus treatment. All data are presented as mean±SEM. Significance versus 
PBS treatment is determined using an ordinary one- way analysis of variance (ANOVA) with Dunnett’s post hoc test. Correlation 
is determined using Pearson’s correlation tests. Significance levels: *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. DCs, 
dendritic cells; NK, natural killer.
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figure S4F). Interestingly, we observed a large popula-
tion of neutrophils (CD11b+Ly6G+) in untreated KPC3 
tumors, the frequency of which dramatically decreased 
after reovirus administration (online supplemental 
figure S4G). Other myeloid cell lineages, such as macro-
phages (CD11b+F4/80+) and CD11c+ macrophages 
(CD11b+ CD11c+) remained unaffected (online supple-
mental figure S4G). Overall, these analyses revealed that 
replication- competent reovirus converts an immunologi-
cally cold TME with low T- cell infiltration into a site with a 
strongly enhanced abundance of activated effector T cells 
and NK cells and reduced frequency of neutrophils and 
immunosuppressive regulatory T cells.
Next, we investigated the mechanism underlying the 
increased T- cell density in the tumor after reovirus admin-
istration. First, we assessed the proliferation of T cells by 
measuring the frequency of intratumoral Ki67+ T cells 
(figure 3G). The fraction of Ki67+ T cells was significantly 
increased after reovirus treatment, especially in CD8+ T 
cells. We subsequently examined if the increased T- cell 
frequencies were solely the result of local proliferation in 
the tumor or were the result of increased attraction to the 
tumor. To this end, T- cell egress from lymph nodes was 
blocked with FTY720 during this experiment (figure 3H,I 
and online supplemental figure S4H,I).32 Interestingly, 
the reovirus- induced increase in intratumoral CD3+ T 
cells, both CD4+ and CD8+ subsets, was completely abro-
gated under FTY720 conditions, whereas the abundance 
of total CD45+ immune cell infiltrate into the tumor was 
not affected.
Finally, we examined the specificity of the tumor- 
infiltrating CD8+ T cells. Tumor- infiltrating lymphocytes 
were cocultured for 6 hours with KPC3 tumor cells, MHC 
class I- matched control TC1 tumor cells or TC1 cells 
infected with reovirus (figure 3J,K). No tumor- specific 
response to KPC3 could be detected, but 10% of the 
CD8+ T cells responded to reovirus- infected TC1 cells by 
producing interferon gamma (IFNγ). This population of 
reovirus- specific T cells was specifically enriched at the 
site of the tumor since their frequencies were around 
1% in the spleen (online supplemental figure S4J). We 
concluded that reovirus replication in the tumor leads to 
strong recruitment of proliferating and activated type 1 T 
cells, which are reovirus- specific.
Combination treatment of reovirus and CD3-bsAbs induces 
strong tumor regression of established TRP1-expressing 
tumors
The observation that reovirus replication ignites a strong 
influx of T cells in the otherwise immunologically cold 
KPC3 tumors provided a strong rationale to evaluate 
the combination of reovirus with CD3- bsAb therapy. 
C57BL6/J mice with palpable TRP1- expressing KPC3 
tumors were treated intratumorally with reovirus and 4 
days later, when the inflammatory response had reached its 
full potential, CD3xTRP1 bsAbs were systemically admin-
istered (figure 4A). This combination resulted in striking 
tumor regressions that started directly after the first bsAb 
injection, whereas bsAbs or reovirus monotherapy hardly 
showed any tumor growth delay (figure 4B and online 
supplemental figure S5A). Visualizing the relative change 
in tumor size after start of bsAb injection indicated that 
combination therapy induced tumor regressions in all 
treated mice, whereas tumors treated with CD3xTRP1 
bsAb monotherapy all increased in size (figure 4C). Mice 
receiving the combination treatment had significantly 
lower tumor volumes on day 21 (figure 4B) and survived 
significantly longer (figure 4D) compared with PBS or 
both monotherapies.
Despite the striking regressions induced by the combi-
nation therapy, durable responses were not observed, 
and all tumors eventually escaped immune control 
(figure 4B–D and online supplemental figure S5A). This 
escape could not be prevented by an additional treatment 
round of reovirus and CD3xTRP1 bsAbs (online supple-
mental figure S5B,C) or by the addition of checkpoint 
blockade using αPD- L1 (online supplemental figure 
S5D–F). We aimed to explain the escape mechanism and 
first assessed T- cell presence in end- stage tumors. Immu-
nohistochemical analysis of these samples indicated that 
CD3+ T cells were still abundantly present in tumors from 
combination- treated animals (online supplemental figure 
S6A). Flow cytometry analysis confirmed the increased 
presence of mainly CD8+ T cells in the tumors that were 
treated with reovirus and CD3xTRP1 (online supple-
mental figure S6B) and additionally revealed that most 
of these T cells still displayed an activated phenotype with 
high expression of CD44 and absence of CD62L (online 
supplemental figure S6C). Furthermore, no striking 
differences in the expression of checkpoint molecules 
programmed cell death protein-1 (PD1), T- cell immuno-
globulin and mucin- domain containing-3 (TIM-3) and 
NKG2A were observed between T cells from the combi-
nation group and T cells from the CD3xTRP1 group 
(online supplemental figure S6C). These data indicated 
that the observed tumor escape could not be explained 
by the absence or exhaustion of intratumoral T cells.
We then looked at tumor- intrinsic factors and analyzed 
the presence of surface TRP1+ cells within the CD45- 
tumor cell population (figure 4E,F and online supple-
mental figure S6D). Importantly, we found that TRP1 
expression was lost in nearly all tumor cells after combi-
nation treatment, versus 40% in tumors treated with 
CD3xTRP1 alone and <20% of cells in the other groups 
(figure 4E,F). These data imply that the robust immune 
pressure of combination treatment initially resulted in 
striking tumor regressions, but also promoted the selec-
tive expansion of TRP1- negative tumor cell clones that 
are insensitive for CD3xTRP1 bsAb targeting. The TRP1 
protein was selected as a model antigen in this study; 
however, it is not an essential molecule for cell growth or 
survival and could therefore be lost without consequences 
for tumor growth. We concluded that this combination 
therapy led to complete eradication of TRP1- expressing 
tumor cells, concomitantly leading to escape of tumor 
variants that lost the targeted antigen.
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Figure 4 Combination treatment of reovirus and CD3xTRP1 bispecific antibodies (bsAbs) induces regression of established 
TRP1- expressing tumors. (A) Design of experiment described in (B–F). Mice (n=8–10/group) with established KPC3.TRP1 
tumors were intratumorally (i.t.) injected with reovirus (107 plaque- forming units (pfu)) on 3 consecutive days. After 4 days, 
mice received intraperitoneal (i.p.) injections of 12.5 µg CD3xTRP1 bsAbs (CD3xTRP1) or phosphate- buffered saline (PBS) 
as control. (B) Average tumor growth curves±SEM. Dashed lines indicate timing of injection with reovirus (blue) or CD3xTRP1 
(red). Differences in mean tumor volumes versus reovirus+CD3xTPR1 treatment on day 21 are determined by one- way analysis 
of variance (ANOVA) with Dunnett’s post hoc test. (C) Relative changes in tumor volume of individual mice from the start of 
CD3xTRP1 bsAb treatment. Indicated is the number of mice with tumor regressions. (D) Kaplan- Meier survival graphs of mice 
in indicated treatment groups. (E) Overlayed dot plots indicating percentage of TRP1+ cells on representative tumors of each 
group. Black dots show background staining of secondary antibody. Red dots show staining using primary αTRP1 antibody 
followed by the secondary antibody. (F) Quantification of TRP1 expression. Dashed line indicates mean background staining 
of secondary antibody. Data represent mean±SEM. (G) Design of experiment described in (H–J). Mice (n=8–10/group) with 
established B16.F10 tumors were i.t. injected with reovirus (107 pfu) on 3 consecutive days. After 4 days, mice received i.p. 
injections of 12.5 µg CD3xTRP1 bsAbs or PBS as control. (H) Individual growth curves of B16.F10- bearing mice receiving 
indicated treatments. (I) Relative changes in tumor volume from start of CD3xTRP1 bsAb treatment. Indicated is the number of 
mice with tumor regressions. (J) Kaplan- Meier survival graphs of mice in indicated treatment groups. Log- rank test was used to 
compare differences in survival. Significance levels: *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.
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To demonstrate the efficacy of this combination treat-
ment in another immunologically cold tumor model, we 
employed the murine melanoma model B16.F10,33 which 
spontaneously expresses the melanocyte- lineage antigen 
TRP1. Although all B16.F10 cells expressed TRP1 on 
their cell surface, the level of expression in B16.F10 was 
a magnitude lower compared with KPC.TRP1 (online 
supplemental figure S7A). In vitro, reovirus was able to 
efficiently replicate in B16.F10 cells; however, the number 
of viral copy numbers and the frequency of sigma 3+ cells 
was lower compared with KPC3 (online supplemental 
figure S7B,C). Interestingly, despite viral replication in 
B16.F10 cells, oncolysis hardly occurred, even at an MOI 
of 100 (online supplemental figure S7D). In vivo, reovirus 
Figure 3 Replication- competent reovirus recruits virus- specific T cells to the tumor. (A) Frequency of CD45+ immune cells 
in the tumor on indicated days post injections (p.i.) of reovirus or UV- inactivated reovirus (UVi) (n=5/group). (B) Frequency of 
CD3+ T cells within CD45+ immune cells in the tumor. (C) Frequency of CD8+ and CD4+ T cells within CD45+ immune cells in 
tumors after reovirus treatment. (D) Ratio between intratumoral CD8+ and CD4+ T cells. (E) Representative images obtained 
from immunohistochemical staining of tumors for CD8 (light brown). Arrows indicate CD8+ cells. Scale bars equal 1 mm and 50 
µm for overview and magnification, respectively. (F) Composition of CD45+ immune infiltrate in the tumor, 5 days after reovirus 
treatment. (G) Frequency of Ki67+ cells within CD3+, CD8+ and CD4+ T- cell populations in the tumor. (H) Design of experiment 
described in (I). Mice (n=3–5/group) with established KPC3 tumors were intratumorally injected with reovirus (107 plaque- 
forming units (pfu)) on 3 consecutive days and were treated with FTY720 (2.5 µg/mL FTY720 in drinking water and daily oral 
administration of 2 µg/g body weight). (I) Frequency of CD3+, CD8+ and CD4+ T- cell populations in the tumor. (J) Representative 
flow cytometry plots for the frequency of interferon gamma (IFNγ)+ cells within the intratumoral CD8+ T- cell population 7 days 
after reovirus treatment. Single- cell suspensions from tumor samples (n=8/group) were cocultured with indicated targets for 
6 hours. Medium was used as negative (Neg.) and phorbol 12- myristate 13- acetate (PMA)/ionomycin was used as positive 
(Pos.) control, respectively. (K) Quantification of IFNγ+ cells within CD8+ T- cell population. All data are presented as mean±SEM. 
Statistical tests used: (A–D): ordinary one- way analysis of variance (ANOVA) with Dunnett’s post hoc test. (G): Multiple unpaired 
t- tests. (I): ordinary one- way ANOVA with Tukey’s post hoc test. (K): unpaired t- test between Neg. control and TC1+reovirus. 
Significance levels: *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.
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was able to efficiently replicate (online supplemental 
figure S7E) and to increase the T- cell density in estab-
lished subcutaneous B16.F10 tumors after intratumoral 
injection (online supplemental figure S7F). Earlier, we 
reported that CD3xTRP1 significantly delayed tumor 
growth in B16.F10 tumors, when given early after tumor 
challenge.25 Similar to the KPC3.TRP1 model, the combi-
nation regimen of reovirus and CD3xTRP1 was required 
to induce tumor regressions in established B16.F10 
tumors (figure 4G,H). Whereas CD3xTRP1 monotherapy 
delayed tumor growth in some animals (figure 4H), 
therapy- mediated tumor regressions were exclusively 
found in 7 out of 10 animals of the combination group 
(figure 4I). The combination treatment also significantly 
prolonged survival (figure 4J).
Combination of reovirus and CD3-bsAbs is effective in a 
human, orthotopic HER2+ breast cancer model
Additionally, we aimed to investigate the efficacy of the 
combination of reovirus and CD3- bsAbs in a more clin-
ically relevant setting. We employed the HER2 positive 
breast cancer model BT474,34 as a close- to- patient model 
to test CD3xHER2 bsAb therapy. BT474 cells express high 
levels of HER2 and were susceptible to reovirus replica-
tion (figure 5A,B). BT474 tumors were engrafted orthot-
opically in the fourth mammary fat pad of NSG mice, and 
human PBMCs were intravenously administered as source 
of effector cells before reovirus and bsAb administration 
(figure 5C). In contrast to our experiments in immuno-
competent mice, reovirus alone already showed some 
efficacy by impairing tumor growth (figure 5D). Whereas 
CD3xHER2 monotherapy had no therapeutic efficacy in 
comparison to the PBS- treated group, the combination 
of reovirus with CD3xHER2 bsAbs induced strong tumor 
regressions in all animals (figure 5D) and a significant 
average tumor shrinkage calculated from the moment 
of PBMC injection (figure 5E). Collectively, these results 
show that the efficacy of bsAb therapy in immunologically 
cold, solid tumors such as KPC3, B16.F10 and BT474 can 
be greatly enhanced by a prior sensitization with reovirus.
Treatment sequence is important for the synergistic effect of 
the reovirus and CD3-bsAb combination therapy
Here, we used two separate treatment modalities applied 
sequentially, but alternatively genes coding for T- cell- 
engaging antibodies can also be introduced into OVs as 
transgenes.35 For this reason, we investigated whether 
timing was important for the observed synergistic effect 
and if comparable tumor regressions could also be 
observed if reovirus and CD3xTRP1 bsAbs were admin-
istered simultaneously or in reversed order (figure 6). 
Interestingly, steady tumor growth without any regressions 
was observed when we switched the sequence of treat-
ment arms and first administered bsAbs (figure 6A,D). 
Simultaneous administration of CD3- bsAbs at the day 
of reovirus injection did induce regressions in tumor 
volume, but tumors started to regrow fast (figure 6B,D). 
Our previous regimen of reovirus before bsAbs led to 
significantly smaller tumor volumes on day 23 after tumor 
challenge, indicating more durable and deeper regres-
sions compared with the other regimens (figure 6C,D). 
Importantly, simultaneous treatment with reovirus and 
bsAbs did induce small regressions, but these occurred 
when tumor volumes were still relatively low at the start 
of CD3- bsAb treatment (figure 6E). In contrast, pretreat-
ment with reovirus caused tumors to undergo steeper 
regressions, even though the tumor volume was signifi-
cantly higher at the start of CD3- bsAb treatment. All 
combination treatment regimens significantly improved 
survival in comparison to the untreated group, but the 
exploitation of reovirus as a preconditioning regimen 
performed significantly better compared with both other 
schedules (figure 6F). In conclusion, these data highlight 
the importance of sensitization of tumors with reovirus 
preceding CD3- bsAb treatment to optimally harness the 
full potential of this combination.
Intratumorally injected reovirus sensitizes local and distant 
cold tumors for subsequent treatment with CD3xTRP1 
therapy
In previous experiments, we observed that intratumoral 
delivery of reovirus also induced systemic activation of 
both CD8+ and CD4+ T cells in the spleen, reflected by 
increased expression of CD44, KLRG1 and PD1, and 
absence of adhesion molecule CD62L (figure 7A). To 
evaluate the possible systemic effects of local reovirus 
administration, a bilateral tumor model was used. Mice 
were engrafted with a subcutaneous KPC3 tumor on the 
right flank and 1 week later received another tumor on 
the left flank (figure 7B). After reovirus treatment, we 
assessed the presence of reovirus copy numbers in both 
the injected (local) and the non- injected (distant) tumor. 
To our surprise, we detected a significantly increased 
number of viral genomic copies in the distant tumor 
after reovirus treatment, although at lower numbers 
than in the injected tumor (figure 7C). Interestingly, no 
increase of reovirus copy numbers could be observed in 
other organs except for the tumor- draining lymph node 
(TDLN) (figure 7D). The presence of reovirus in the 
distant tumor also led to an increased expression of a 
selection of IFN- stimulated genes (ISGs) (figure 7E) and 
subsequent increased influx of CD8+ T cells, indicating 
that locally injected reovirus can find its way to distant 
tumors and is associated with the recruitment of immune 
cells there (figure 7F). We then investigated whether our 
combination treatment could also effectively control the 
growth of distant tumors. As expected, monotherapy with 
CD3xTRP1 bsAbs did not affect the tumor growth of local 
or distant tumors (figure 7G). Strikingly, combination 
treatment also induced regression of the distant KPC3.
TRP1 tumors (figure 7H). This effect was TRP1 targeted, 
since no regressions were observed in distant tumors not 
expressing TRP1 (KPC3). These findings suggest that the 
combination of reovirus and CD3- bsAbs might also be 
effective in metastatic disease.
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Intravenous administration of reovirus is also effective in 
preconditioning the TME
In the present study, reovirus was injected intratumorally 
to ensure efficient delivery at the tumor site. However, 
in most clinical studies, intravenous infusion of reovirus 
has been applied36 and effective delivery to tumor sites, 
including the brain, was demonstrated.11 We therefore 
tested the therapeutic efficacy of systemic delivery of 
reovirus (figure 8A). Intravenous administration of 107 
and 108 pfu/injection resulted in detectable numbers 
of reovirus genomic copies in the tumor, although in 
significantly lower numbers compared with intratu-
moral administration of 107 pfu of reovirus (figure 8B). 
Increased expression of a selection of ISGs was observed 
in comparison to the PBS group (figure 8C), suggesting 
that intravenously administered reovirus is able to induce 
Figure 5 Combination of reovirus and CD3- bispecific antibodies (bsAbs) is effective in a human, orthotopic human epidermal 
growth factor receptor (HER2)+ breast cancer model. (A) HER2 expression percentages on BT474 cells, as analyzed by flow 
cytometry using a two- step protocol. (B) Number of reovirus genomic segment 4 (S4) copies in BT474 cells after reovirus 
infection. BT474 cells (200,000/well) were infected with reovirus multiplicities of infection (MOI) 10 or phosphate- buffered 
saline (PBS) (Mock) as a control. Samples (n=3) were harvested 24 hours after infection and the number of viral S4 copies was 
determined by quantitative reverse transcription PCR. (C) Design of experiment described in (D and E). Mice (n=6/group) with 
established BT474 tumors were intravenously (i.v.) injected with 5×106 human PBMCs, and thereafter intratumorally (i.t.) injected 
with reovirus (107 plaque- forming units (pfu)) on 2 consecutive days. After 4 days, mice received intraperitoneal (i.p.) injections 
of 12.5 µg CD3xHER2 bsAbs (CD3xHER2) or PBS as control. (D) Individual growth curves of BT474- bearing mice receiving 
indicated treatments. Lines indicate timing of injection with PBMCs (orange), reovirus (blue) or CD3xHER2 (red). (E) Average 
relative changes (±SEM) in tumor volume from start of CD3xHER2 bsAb treatment. Significance versus PBS on day 42 was 
calculated using one- way analysis of variance with Dunnett’s post hoc test. Significance level: **p<0.01.
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an IFN response in the TME. Intravenous administration 
of reovirus was effective as a preconditioning method, 
since tumor outgrowth was temporarily halted, but no 
regressions were observed as was the case after intratu-
moral administration (figure 8D–F). Mice treated with 
any of the combination treatments had smaller tumor 
volumes (figure 8E) and significantly prolonged survival 
times (figure 8F) in comparison to the untreated group. 
These data imply that preconditioning of the TME with 
both intravenous and local administration of reovirus is 
effective to turn CD3- bsAbs into a potent immunotherapy 
for solid cancers. Collectively, our data demonstrate 
that replication- competent reovirus turns an otherwise 
unsuccessful CD3- bsAb therapy into a powerful systemic 
treatment.
DISCUSSION
In this study, we demonstrated that preconditioning of 
the TME with oncolytic reovirus is an attractive strategy to 
prime immunologically cold tumors for T- cell- engaging 
antibody therapy (Graphical abstract). Tumor- selective 
replication of competent reovirus converted the TME to 
an inflamed site with a strong IFN signature and T- cell- 
attracting chemokines, followed by an enhanced influx 
of NK cells and activated T cells. Subsequent systemic 
administration of T- cell- engaging antibodies induced 
strong tumor regressions of reovirus- injected and distant 
non- injected lesions, implying that this strategy may be 
effective for the treatment of metastatic disease.
Although OVs are considered potent anticancer modal-
ities, reovirus and several others have demonstrated 
Figure 6 Treatment sequence is important for the synergistic effect of the reovirus and CD3- bispecific antibody (bsAb) 
combination therapy. Treatment schedule and individual tumor growth curves of mice (n=8–10/group) that received 
intraperitoneal injections (i.p.) (12.5 µg/mouse) of CD3xTRP1 bsAbs before (A), simultaneously with (B) or after (C) intratumoral 
(i.t.) reovirus injections (107 plaque- forming units (pfu)/mouse). Dashed vertical lines indicate timing of injection with reovirus 
(blue) or CD3xTRP1 (red). (D) Average tumor growth curves±SEM of experimental groups shown in (A–C) compared with PBS 
treatment. Significance versus reovirus+CD3xTPR1 treatment on day 23 is determined by comparing tumor volumes using a 
one- way analysis of variance (ANOVA) with Dunnett’s post hoc test. (E) Mean±SEM tumor volume at the start of CD3xTRP1 
bsAb treatment for treatment schedules CD3xTRP1+reovirus (day 13), reovirus/CD3xTRP1 (day 13) and reovirus+CD3xTRP1 
(day 19). Ordinary one- way ANOVA with Tukey’s post hoc test was used to compare means. (F) Kaplan- Meier survival curves of 
mice in different treatment schedules. Log- rank test was used to compare differences in survival. Significance levels: **p<0.01, 
***p<0.001 and ****p<0.0001.
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Figure 7 Intratumorally- injected reovirus sensitizes local and distant cold tumors for subsequent treatment with CD3xTRP1 
therapy. (A) Expression of activation markers on splenic CD8+ or CD4+ T cells 5 days after reovirus or phosphate- buffered 
saline (PBS) administration (n=5/group). (B) Treatment schedule of experiment described in (C–G). Mice (n=8–10/group) were 
subcutaneously inoculated with KPC3.TRP1 cells in the right flank. Seven days later, another KPC3.TRP1 or KPC3 tumor was 
inoculated in the left flank. Mice received intratumoral (i.t.) injections of reovirus (107 plaque- forming units (pfu)) in the primary 
right tumor. Then, mice were sacrificed for intratumoral analysis at 3 and 7 days post reovirus injections (p.i.) (panels C–F; 
pooled results of two independent experiments with similar results) or mice received subsequent intraperitoneal (i.p.) injections 
of 12.5 µg CD3xTRP1 bispecific antibodies (bsAbs) and tumor size was monitored (panels G and H). (C) Reovirus genomic 
segment 4 (S4) copy numbers in local and distant tumors 3 days after reovirus treatment or PBS as control. (D) S4 copy 
numbers present in other organs of reovirus- treated mice 3 days after reovirus administration. Dashed horizontal line represents 
average S4 copy numbers in PBS- treated mice. (E) Heatmap of relative expression of interferon response genes in local and 
distant tumor as determined by quantitative reverse transcription PCR. Numbers indicate fold change versus PBS- treated local 
tumors. (F) Frequency of T cells in local and distant tumors of mice 7 days after local reovirus administration. Data presented as 
mean±SEM. Differences between PBS and reovirus in panels A and C–F were determined with unpaired t tests. (G) Individual 
tumor growth curves of local and distant tumors of mice (n=8/group) treated with CD3xTRP1. Dashed red lines indicate timing 
of injection. (H) Individual tumor growth curves of local and distant TRP1- expressing (KPC3.TRP1) or wild- type (WT) KPC3 
tumors of mice after i.t. treatment with reovirus and subsequent i.p. injections with CD3xTRP1. Dashed lines indicate timing 
of injection with reovirus (blue) or CD3xTRP1 (red). Significance levels: *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. TDLN, 
tumor- draining lymph node.
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limited therapeutic efficacy when used as a monotherapy. 
Since oncolytic activity may not be the main asset of 
reovirus as anticancer therapeutic, we focused on its 
potential to modify the TME. RNA viruses typically repli-
cate with fast kinetics and induce a very potent type I 
IFN response.37 Indeed, our analysis of reovirus- induced 
immune dynamics revealed a very fast and potent induc-
tion of intratumoral IFN response, followed by a robust 
influx of T cells. UV- inactivated, replication- incompetent 
reovirus did not induce an IFN gene signature and T- cell 
influx in the TME, although it still contains pathogen- 
associated molecular patterns (PAMPs) that may be 
recognized by PRRs.38 Although UV- inactivated reovirus 
has shown to be effective in the induction of tumor- 
specific T cells by human DCs in an in vitro setting,31 in 
our in vivo setting replication was required to induce a 
potent IFN response and subsequent T- cell infiltration 
into the tumor. In contrast, modified vaccinia virus did 
Figure 8 Intravenous (i.v.) administration of reovirus is also effective in preconditioning the tumor microenvironment. (A) 
Design of experiment described in (B–F). KPC3.TRP1- bearing mice were intratumorally (i.t.) or i.v. injected with reovirus (107 
or 108 plaque- forming units (pfu)) on 3 consecutive days. Tumors were harvested 3 days after the last reovirus injection for 
intratumoral analysis (n=3–4/group) or received intraperitoneal (i.p.) injections of 12.5 µg CD3xTRP1 bispecific antibodies 
(bsAbs) (CD3xTRP1) or phosphate- buffered saline (PBS) as control (n=6–7/group). (B) Reovirus genomic segment 4 (S4) copy 
number in tumor lysates by quantitative reverse transcription PCR (RT- qPCR). Mean±SEM. (C) Heatmap of relative expression 
of interferon response genes in tumors versus phosphate- buffered saline (PBS) treatment, as determined by RT- qPCR. (D) 
Individual tumor growth curves of KPC3.TRP1- bearing mice (n=6–8/group) that were i.t. or i.v. injected with reovirus (107 or 
108 pfu) on 3 consecutive days. After 4 days, mice received i.p. injections of 12.5 µg CD3xTRP1 bsAbs (CD3xTRP1) or PBS as 
control. Dashed vertical lines indicate timing of injection with reovirus (blue) or CD3xTRP1 (red). (E) Average±SEM tumor growth 
curves. Differences in mean tumor volumes versus PBS treatment on day 21 are determined by one- way analysis of variance 
with Dunnett’s post hoc test. (F) Kaplan- Meier survival curves of mice. Log- rank test was used to compare differences in 
survival. Significance levels: *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.
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induce intratumoral inflammation and T- cell influx after 
inactivation, indicating that this OV holds sufficient viral 
PAMPs in the absence of viral replication.39
Intratumoral injections lead to “islands” of reovirus 
production within the tumor, resulting in local amplifi-
cation and release of virus particles. Concomitantly, we 
found viral spread in the animals from injected tumors 
to distant non- injected tumors, without affecting healthy 
tissues except for low levels in the TDLN. Previous work 
already showed that various cell types such as T cells, DCs, 
monocytes and granulocytes can act as cellular carriers 
and deliver infectious reovirus particles to tumor cells, 
even in the context of pre- existing antiviral immunity.40–42 
We speculate that one of these immune cell types is 
involved in carrying infectious reovirus particles via the 
TDLN to distant tumors. Further research is required 
to elucidate the exact cellular carrier or if reovirus can 
migrate without any cellular carrier.
Local versus systemic delivery of OVs is a huge topic 
of debate. Local delivery of OVs is in clinical practice 
for talimogene laherparepvec (T- VEC)13 43 and is used 
in many preclinical studies including the present study 
to ensure efficient delivery to the tumor site.12 However, 
in most clinical studies, reovirus is administered intrave-
nously.11 36 One advantage of intravenous delivery is that 
it does not rely on injectable tumor lesions, which are not 
available in the majority of cancer types. Here, we showed 
that intravenously injected reovirus is able to reach the 
tumor and sensitize tumors for subsequent CD3- bsAb 
therapy. However, the antitumor efficiency of the combi-
nation with CD3- bsAbs is lower when compared with 
intratumorally injected reovirus. Even a 10- fold higher 
dose of systemically administered reovirus significantly 
underperformed intratumoral delivery, suggesting that 
intravenous delivery would need to be improved to reach 
its full potential. One previously suggested method to 
enhance reovirus delivery is to load reovirus on the afore-
mentioned cellular carriers.40 Nevertheless, the efficacy 
of the intravenous delivered reovirus in this model is an 
important finding since it paves the way for clinical appli-
cation of such a combination regardless of the tumor 
location and route of administration.
Reovirus and other OVs have already demonstrated to 
combine well with checkpoint blockade, a therapy that 
depends on the presence of tumor- specific T cells.10–12 
OVs and T- cell- engaging antibody therapy is an emerging 
and exciting new field of research. We demonstrated 
that prior sensitization with reovirus greatly enhanced 
the efficacy of CD3- bsAb therapy in immunologically 
cold tumors. However, others introduced bispecific 
T- cell engagers (BiTE) as transgenes into OVs.44–47 For 
instance, treatment with oncolytic measles virus encoding 
CD3- BiTEs demonstrated delayed tumor growth and 
prolonged survival in immunocompetent C57BL/6J 
mice harboring subcutaneous MC38 or B16 tumors.44 
Similarly, oncolytic adenovirus engineered with a CD3- 
BiTE targeting epidermal growth factor receptor (EGFR) 
and an oncolytic vaccinia virus encoding a CD3xEPHA2 
BiTE showed antitumor activity in xenograft models and 
an oncolytic adenovirus encoding a CD3- BiTE targeting 
epithelial cell adhesion molecule (EpCAM) was able to 
activate endogenous T cells to kill tumor cells in primary 
human tumor samples of malignant peritoneal ascites 
and pleural exudates.45–47 Although encoding bsAbs or 
BiTEs in OVs has several advantages such as reduction 
of treatment burden for patients,35 our data imply that 
these strategies do not exploit the full potential of this 
combination therapy as the T- cell influx peaks around 
a week after reovirus application, when viral genomic 
copies start to decline. In the studies with BiTE- encoding 
OVs, the kinetics of expression of the transgene may not 
parallel the kinetics of the OV- induced T- cell activation, 
especially since BiTE molecules have a very short half- life 
due to their small size and the absence of a stabilizing 
Fc tail.3 Most of the T- cell- engaging activity might already 
be declined at the peak of T- cell attracting chemokines. 
We therefore advocate to separate the administration of 
OVs from bsAbs and consider OV injection as a precondi-
tioning strategy. Further research is, however, warranted 
to fully understand the optimal regimen of OV and bsAb 
delivery, including the biodistribution of the OVs and 
bsAbs, and how this differs between OVs, bsAbs and even 
tumor types.
The mechanism of action of CD3- bsAbs is not yet 
completely understood. For instance, in our studies, we 
did not assess whether CD3xTRP1 bsAbs first bind TRP1 
in the tumor and then engage T cells that are infiltrating 
into the tumor due to reovirus- induced inflammation, or 
if bsAbs bind T cells in the lymph node, spleen or the 
circulation and subsequently activate these T cells on 
binding of TRP1 in the tumor.4 Elucidating this mode 
of- action might be important to further harness the full 
potential of CD3- bsAbs as a monotherapy and in combi-
nation with OVs since it will guide future improvements 
in therapeutic efficacy.
Importantly, our data demonstrated that the combina-
tion of OV and CD3- bsAbs is an extremely powerful therapy 
that imposed a strong, immunological selective pressure 
on the tumors, leading to initial regressions but later on 
in relapsed tumors that lost expression of the antigen. We 
used the melanoma- associated antigen TRP1 as a well- 
known model antigen. This surface- expressed protein is 
involved in melanin production but is not essential for 
cell growth or survival. The use of this particular model 
antigen allowed us to investigate therapy resistance on the 
one hand, but on the other can be considered a limita-
tion of our study. It emphasizes the importance of the 
careful selection of the targeted antigen when this combi-
nation strategy is translated to the clinic. For effective 
bsAb therapy in humans, the ideal target antigen needs 
to be selectively and abundantly expressed on tumor cells 
but should also be essential for tumorigenesis. One such 
target is HER2, and we employed human CD3xHER2 as 
the second bsAb to demonstrate proof- of- concept of our 
combination strategy in the HER2+ BT474 model. In this 
model, we observed some close- to- complete regressions, 
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but we were not able to determine durable responses in 
these animals due to increasing viremia over time, which 
we attributed to the lack of a functional adaptive immune 
system in these NSG mice. Although HER2 and other 
classical TAAs such as EpCAM and EGFR represent attrac-
tive targets, they are not entirely tumor specific. So- called 
“on- target, off- tumor toxicity” might limit the therapeutic 
potential of these targets.48 49
Instead, targeting of highly tumor- specific antigen 
glypican-3 (GPC3) or the tumor- specific mutant of EGFR 
(EGFRvIII) showed limited and manageable toxicity, and 
striking antitumor efficacy in immunocompetent mouse 
models or patients with recurrent glioblastoma.50 51 These 
data illustrate that further extensive target discovery and 
testing is required to create safe and effective bsAbs for 
clinical use. The intracellular proteome might even be 
considered as a good target for bsAbs, via surface display 
of tumor- specific peptide/MHC complexes.52
Together, our data demonstrate that combined local 
reovirus treatment and systemic T- cell- engaging antibody 
therapy induces strong tumor regressions of both local 
and distant solid tumors. Both CD3- bsAbs and OVs are 
already undergoing rigorous clinical testing, suggesting a 
possible fast translation of our work to the clinic.
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